https://doi.org/10.55788/9c800d3b
The AIR (NCT00214526) trial assessed the safety and efficacy of C21 in 60 patients with IPF [1]. Prof. Toby Maher (Keck School of Medicine, University of Southern California, CA, USA), who presented the data of the current interim analysis, emphasised that the baseline characteristics of the included patients were in line with other trials that included either treatment-naïve patients or patients that were not treated with the standard-of-care.
At 36 weeks, C21 displayed a significant positive impact on forced vital capacity compared with baseline (P<0.001). Prof. Maher added that C21 was still efficacious if a ‘worst-case-scenario’ was wielded for the missing data (P<0.01). Importantly, C21 appeared to be a safe and tolerable agent. “There were no serious gastro-intestinal side effects,” commented Prof. Maher. “The only adverse event that occurred in >10% of the patients was hair loss, more frequently seen in the higher dose groups.” He added that, compared with nintedanib, the safety profile of C21 looks promising.
Prof. Maher concluded that the results of the AIR trial indicate that treatment with C21 is safe and may lead to disease stabilisation in patients with IPF.
- Batta R, et al. An updated interim analysis of the Air trial: an open-label single-arm 36 week phase 2 trial of an angiotensin type 2 receptor agonist, C21, in individuals with IPF. Session A99, ATS International Conference 2023, 19–24 May, Washington DC, USA.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Can camlipixant improve quality of life of patients with refractory chronic cough? Next Article
Novel clinical score for predicting laryngopharyngeal reflux »
« Can camlipixant improve quality of life of patients with refractory chronic cough? Next Article
Novel clinical score for predicting laryngopharyngeal reflux »
Table of Contents: ATS 2023
Featured articles
TORREY trial: seralutinib associated with reduced pulmonary vascular resistance in PAH
Practice-changing results for ensifentrine in COPD
Asthma
Vitamin D for asthma protection: what is the optimal timing?
Remarkable results for novel biologic therapy for asthma
Success for fluticasone furoate plus vilanterol in uncontrolled asthma
COPD
Practice-changing results for ensifentrine in COPD
Alvelestat for AATD meets primary endpoints in phase 2 trial
Fewer exacerbations with dupilumab in COPD with type 2 inflammation
New AATD therapy may alleviate treatment burden for patients
Efficient detection of AECOPD with at-home vital signs monitoring
COVID-19
COVA trial: success for the investigational agent sarconeos in hospitalised COVID-19
Mitochondrial DNA levels predict COVID-19 severity
Other
Excellent results for C21 in idiopathic pulmonary fibrosis
Can camlipixant improve quality of life of patients with refractory chronic cough?
TORREY trial: seralutinib associated with reduced pulmonary vascular resistance in PAH
Improving quality care in sepsis through machine learning models
Can information technology improve guideline adherence in sepsis care?
Related Articles
October 29, 2020
CPAP withdrawal has negative consequences for sleep apnoea patients
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy